铂-话题@MedSci

#铂#

382篇内容 | 6069人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1737644, encodeId=91e21e3764490, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, objectType=article, longId=196267, objectId=c95e19626e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95e19626e25, replyNumber=0, likeNumber=75, createdTime=2020-12-15, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95e19626e25, moduleTitle=Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95e19626e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737638, encodeId=b4591e3763862, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet Oncol :Atezolizumab联合卡波铂和nab-paclitaxel用于非小细胞肺癌术前化疗, objectType=article, longId=193903, objectId=aa88193903cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa88193903cd, replyNumber=0, likeNumber=57, createdTime=2020-06-02, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa88193903cd, moduleTitle=Lancet Oncol :Atezolizumab联合卡波铂和nab-paclitaxel用于非小细胞肺癌术前化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa88193903cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737637, encodeId=ef591e37637ea, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, objectType=article, longId=192935, objectId=dc37192935a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc37192935a7, replyNumber=0, likeNumber=82, createdTime=2020-11-30, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc37192935a7, moduleTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc37192935a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737630, encodeId=f50a1e3763092, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Cancers (Basel)：鞘氨醇1-磷酸受体2能够诱导顺铂治疗的耳保护反应, objectType=article, longId=186877, objectId=41fb1868e757, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41fb1868e757, replyNumber=0, likeNumber=67, createdTime=2020-02-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41fb1868e757, moduleTitle=Cancers (Basel)：鞘氨醇1-磷酸受体2能够诱导顺铂治疗的耳保护反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41fb1868e757)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737642, encodeId=c0221e37642e4, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期, objectType=article, longId=196146, objectId=c66f19614679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66f19614679, replyNumber=0, likeNumber=63, createdTime=2020-10-10, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66f19614679, moduleTitle=Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66f19614679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737641, encodeId=46f11e3764106, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, objectType=article, longId=195598, objectId=203c1955983f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203c1955983f, replyNumber=0, likeNumber=64, createdTime=2020-12-27, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203c1955983f, moduleTitle=Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203c1955983f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737661, encodeId=232c1e37661b0, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后, objectType=article, longId=201080, objectId=d88e20108084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d88e20108084, replyNumber=0, likeNumber=75, createdTime=2021-08-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d88e20108084, moduleTitle=Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d88e20108084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737651, encodeId=74531e37651fb, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果, objectType=article, longId=198497, objectId=df1419849e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df1419849e05, replyNumber=0, likeNumber=60, createdTime=2020-09-24, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df1419849e05, moduleTitle=Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df1419849e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737656, encodeId=12b81e3765651, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), objectType=article, longId=199903, objectId=f051199903bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f051199903bb, replyNumber=0, likeNumber=85, createdTime=2021-07-31, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f051199903bb, moduleTitle=JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f051199903bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737639, encodeId=b11c1e376390b, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, objectType=article, longId=194245, objectId=b6fe19424555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fe19424555, replyNumber=0, likeNumber=68, createdTime=2020-12-17, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fe19424555, moduleTitle=Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fe19424555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737652, encodeId=669c1e3765247, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, objectType=article, longId=198499, objectId=8e7819849955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e7819849955, replyNumber=0, likeNumber=61, createdTime=2021-02-05, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e7819849955, moduleTitle=J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e7819849955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737633, encodeId=38ac1e37633d9, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=79, createdTime=2020-03-31, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737649, encodeId=b05e1e37649e6, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, objectType=article, longId=198494, objectId=6962198494d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6962198494d6, replyNumber=0, likeNumber=67, createdTime=2021-06-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6962198494d6, moduleTitle=Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6962198494d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737640, encodeId=1f981e3764068, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, objectType=article, longId=194712, objectId=cf45194e12da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf45194e12da, replyNumber=0, likeNumber=56, createdTime=2020-06-14, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf45194e12da, moduleTitle=ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf45194e12da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737629, encodeId=886f1e3762995, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=83, createdTime=2020-06-22, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737623, encodeId=01431e37623dd, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, objectType=article, longId=183027, objectId=fd5a18302e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5a18302e46, replyNumber=0, likeNumber=97, createdTime=2019-12-09, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5a18302e46, moduleTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5a18302e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737626, encodeId=2b4d1e376269c, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=JAMA Otolaryngol Head Neck Surg：头颈癌患者放疗和顺铂化疗后听力损失预测研究, objectType=article, longId=184098, objectId=6cc8184098d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc8184098d1, replyNumber=0, likeNumber=73, createdTime=2020-01-24, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc8184098d1, moduleTitle=JAMA Otolaryngol Head Neck Surg：头颈癌患者放疗和顺铂化疗后听力损失预测研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc8184098d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737635, encodeId=087f1e37635d9, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=Lancet:吉西他滨-铂化疗用于晚期上尿路上皮癌的局部治疗, objectType=article, longId=189914, objectId=531c18991483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=531c18991483, replyNumber=0, likeNumber=72, createdTime=2020-04-13, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=531c18991483, moduleTitle=Lancet:吉西他滨-铂化疗用于晚期上尿路上皮癌的局部治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=531c18991483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737622, encodeId=8b051e3762239, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究, objectType=article, longId=182436, objectId=14db1824369b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14db1824369b, replyNumber=0, likeNumber=74, createdTime=2020-09-23, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14db1824369b, moduleTitle=和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14db1824369b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1737636, encodeId=52ef1e376360a, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=65, createdTime=2020-12-05, rootId=0, userName=ms3153534357578991, userId=ca4034296500, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂

2020-05-29

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Int J Clin Oncol：卡铂或西妥昔单抗加放疗对不能接受顺铂治疗的局部晚期头颈部癌症患者的安全性和有效性

2020-12-15

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet Oncol :Atezolizumab联合卡波铂和nab-paclitaxel用于非小细胞肺癌术前化疗

2020-06-02

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效

2020-11-30

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Cancers (Basel)：鞘氨醇1-磷酸受体2能够诱导顺铂治疗的耳保护反应

2020-02-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：ATR抑制剂联合吉西他滨可延长铂耐药的高级别浆液性卵巢癌患者的无进展存活期

2020-10-10

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet oncol：ARIEL3试验：Rucaparib维持治疗铂敏感性复发性卵巢癌超过2年后的探索性分析

2020-12-27

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Br J Cancer：尼妥珠单抗联合顺铂放疗改善高HIF1α表达的局部晚期头颈部鳞癌患者的预后

2021-08-13

柳叶一刀 (审核中...)

前往app查看评论内容

#铂#

Cancer：二甲双胍联合顺铂和放疗治疗局部晚期头颈部鳞状细胞癌的效果

2020-09-24

柳叶一刀 (审核中...)

前往app查看评论内容

#铂#

JTO：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状NSCLC一线治疗的有效性和安全性(ORIENT-11)

2021-07-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet：Atezolizumab联合铂化疗一线治疗转移性尿路上皮癌

2020-12-17

柳叶一刀 (审核中...)

前往app查看评论内容

#铂#

J Clin Oncol：吉非替尼VS吉非替尼加培美曲塞和卡铂化疗在EGFR突变肺癌中的对比分析

2021-02-05

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2020-03-31

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Radiother Oncol：西妥昔单抗-RT联合阿维单抗可用于治疗不适合顺铂治疗的晚期HNSCC患者

2021-06-13

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

ASCO 2020：奥拉帕利用于BRCA-1/2突变铂敏感复发性卵巢癌患者的疗效及安全性分析（SOLO2研究）

2020-06-14

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-06-22

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期

2019-12-09

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

JAMA Otolaryngol Head Neck Surg：头颈癌患者放疗和顺铂化疗后听力损失预测研究

2020-01-24

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

Lancet:吉西他滨-铂化疗用于晚期上尿路上皮癌的局部治疗

2020-04-13

爆笑小医 (审核中...)

前往app查看评论内容

#铂#

和铂医药宣布启动用于治疗实体瘤的下一代抗CTLA-4抗体的首次临床研究

2020-09-23

ms3153534357578991 (审核中...)

前往app查看评论内容

#铂#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-12-05

科室
- - 订阅+
  - 更多科室
工具
服务